A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
Former Girls Aloud singer Kimberley Walsh is pregnant with her second child, she has revealed.
Chancellor George Osborne will seek to reassure financial markets on Monday morning following Britain's decision to leave the EU.
In his first outing since the referendum result, the lead Leave campaigner has outlined his vision for a post-Brexit Britain.